SMITH & NEPHEW PLC Smith & Nephew Plc Stock OTC Markets
Equities
SNNUF
GB0009223206
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.81 USD | +4.15% |
|
+4.15% | -7.58% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 5.82B | Sales 2025 * | 6.12B | Capitalization | 11.27B |
|---|---|---|---|---|---|
| Net income 2024 * | 541M | Net income 2025 * | 694M | EV / Sales 2024 * | 2.38 x |
| Net Debt 2024 * | 2.56B | Net Debt 2025 * | 2.23B | EV / Sales 2025 * | 2.21 x |
| P/E ratio 2024 * |
21.9
x | P/E ratio 2025 * |
16.8
x | Employees | 18,452 |
| Yield 2024 * |
2.96% | Yield 2025 * |
3.32% | Free-Float | 99.15% |
More Fundamentals
* Assessed data
More news
Latest transcript on Smith & Nephew Plc
More recommendations
More press releases
More news
| 1 day | +4.15% | ||
| 1 week | +4.15% | ||
| Current month | +3.90% | ||
| 1 month | +6.13% | ||
| 3 months | -4.76% | ||
| 6 months | +2.48% | ||
| Current year | -7.58% |
1 week
12.55
12.81
1 month
11.6612.81
Current year
11.6614.27
1 year
10.8016.10
3 years
10.7622.64
5 years
10.7625.50
10 years
10.7625.50
| Managers | Title | Age | Since |
|---|---|---|---|
Deepak Nath
CEO | Chief Executive Officer | - | 22-03-31 |
John Rogers
DFI | Director of Finance/CFO | 56 | Nov. 30 |
Alison Parkes
CMP | Compliance Officer | - | 99-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Marc E. Owen
BRD | Director/Board Member | 65 | 17-09-30 |
Jeremy Maiden
BRD | Director/Board Member | 62 | 23-09-13 |
Rupert Soames
CHM | Chairman | 63 | 23-04-25 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 12.81 | +4.15% | 3,941 |
| 24-05-08 | 12.3 | +0.95% | 752 |
Delayed Quote OTC Markets, May 10, 2024 at 11:43 am EDT
More quotes
Smith & Nephew Plc specializes in designing, manufacturing and marketing medical products and equipment. Net sales break down by activity sector as follows:
- orthopedic surgery (39.9%): primarily orthopedic implants (hips, knees and shoulders);
- sports medicine, arthroscopy and cervicofacial surgery (31.2%): surgery and damaged tissue repair products and instruments, visualization products, etc.;
- wound care (28.9%): skin grafts for major burns victims, treatments for leg ulcers, etc.
The United States accounts for 53.7% of net sales.
Calendar
2024-07-24
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
12.92
USD
Average target price
16.35
USD
Spread / Average Target
+26.49%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.86% | 124B | |
| +4.17% | 9.17B | |
| -21.47% | 4.71B | |
| +8.77% | 3.44B | |
| -6.03% | 2.88B | |
| -12.05% | 2.11B | |
| -7.83% | 2.09B | |
| -22.84% | 1.8B | |
| -8.57% | 1.17B |
- Stock Market
- Equities
- SN. Stock
- SNNUF Stock